Particle.news

Proteomic Classifier Predicts Melanoma Response to Immune Checkpoint Therapy

Validation followed by clinical assay development would allow the protein-based tool to help clinicians choose which patients should receive combination immunotherapy.

Overview

  • The findings were published as two companion, peer-reviewed papers on Nov. 17, 2026 in the AACR journals Cancer Discovery and Clinical Cancer Research, releasing a proteogenomic and proteomic atlas of cutaneous melanoma.
  • The Clinical Cancer Research team analyzed 207–208 pre-treatment tumor samples and identified three reproducible proteomic subtypes—an immune-rich group, a proliferation-featured group, and a growth/metastasis-featured group—with the immune-rich tumors showing the best response to checkpoint blockade.
  • Researchers trained a classifier on tumor protein patterns to assign tumors to the three subtypes and validated its ability to predict treatment response and progression-free survival in two independent patient cohorts.
  • The Cancer Discovery study combined 13 molecular measurements across 183 tumors to map protein fragments shown to immune cells, chemical protein modifications linked to survival, and hundreds of candidate therapeutic targets.
  • Authors and funders say the results could let doctors avoid ineffective, toxic treatments for some patients but stress that larger prospective studies, assay translation to routine pathology, and regulatory validation are required before clinical use.